Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for BioMed Research International, enter your email address in the box below.

Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 859516, 7 pages
http://dx.doi.org/10.1155/2010/859516
Research Article

Expressions of Neuregulin 1 and ErbB4 in Prefrontal Cortex and Hippocampus of a Rat Schizophrenia Model Induced by Chronic MK-801 Administration

Yu Feng,1 Xiao-Dong Wang,1,2 Chun-Mei Guo,1 Yang Yang,1 Ji-Tao Li,1 Yun-Ai Su,1 and Tian-Mei Si1

1Key Laboratory of Mental Health of National Health Ministry, Institute of Mental Health, Peking University, No. 51 Hua Yuan Bei Road, Haidian District, Beijing 100191, China
2Max Planck Institute of Psychiatry, Kraepelinstr. 2-10, 80804 Munich, Germany

Received 16 January 2010; Accepted 22 February 2010

Academic Editor: Xudong Huang

Copyright © 2010 Yu Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Harrison and M. J. Owen, “Genes for schizophrenia? Recent findings and their pathophysiological implications,” The Lancet, vol. 361, no. 9355, pp. 417–419, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. Harrison and D. R. Weinberger, “Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence,” Molecular Psychiatry, vol. 10, no. 1, pp. 40–68, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. A. J. Law, J. E. Kleinman, D. R. Weinberger, and C. S. Weickert, “Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia,” Human Molecular Genetics, vol. 16, no. 2, pp. 129–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Norton, V. Moskvina, D. W. Morris et al., “Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia,” American Journal of Medical Genetics Part B, vol. 141B, no. 1, pp. 96–101, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Silberberg, A. Darvasi, R. Pinkas-Kramarski, and R. Navon, “The involvement of ErbB4 with schizophrenia: association and expression studies,” American Journal of Medical Genetics Part B, vol. 141B, no. 2, pp. 142–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Gerlai, P. Pisacane, and S. Erickson, “Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks,” Behavioural Brain Research, vol. 109, no. 2, pp. 219–227, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. M. S. Golub, S. L. Germann, and K. C. K. Lloyd, “Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse,” Behavioural Brain Research, vol. 153, no. 1, pp. 159–170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Stefansson, E. Sigurdsson, V. Steinthorsdottir et al., “Neuregulin 1 and susceptibility to schizophrenia,” American Journal of Human Genetics, vol. 71, no. 4, pp. 877–892, 2002. View at Google Scholar · View at Scopus
  9. G. D. Fischbach and K. M. Rosen, “ARIA: a neuromuscular junction neuregulin,” Annual Review of Neuroscience, vol. 20, pp. 429–458, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Buonanno and G. D. Fischbach, “Neuregulin and ErbB receptor signaling pathways in the nervous system,” Current Opinion in Neurobiology, vol. 11, no. 3, pp. 287–296, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Mei and W.-C. Xiong, “Neuregulin 1 in neural development, synaptic plasticity and schizophrenia,” Nature Reviews Neuroscience, vol. 9, no. 6, pp. 437–452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Carpenter, “ErbB-4: mechanism of action and biology,” Experimental Cell Research, vol. 284, no. 1, pp. 66–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Lemke, “Glial control of neuronal development,” Annual Review of Neuroscience, vol. 24, pp. 87–105, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. A. N. Garratt, S. Britsch, and C. Birchmeier, “Neuregulin, a factor with many functions in the life of a Schwann cell,” BioEssays, vol. 22, no. 11, pp. 987–996, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. G. V. Michailov, M. W. Sereda, B. G. Brinkmann et al., “Axonal neuregulin-1 regulates myelin sheath thickness,” Science, vol. 304, no. 5671, pp. 700–703, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. K.-A. Nave and J. L. Salzer, “Axonal regulation of myelination by neuregulin 1,” Current Opinion in Neurobiology, vol. 16, no. 5, pp. 492–500, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Taveggia, G. Zanazzi, A. Petrylak et al., “Neuregulin-1 type III determines the ensheathment fate of axons,” Neuron, vol. 47, no. 5, pp. 681–694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. S. E. Arnold, K. Talbot, and C.-G. Hahn, “Neurodevelopment, neuroplasticity, and new genes for schizophrenia,” Progress in Brain Research, vol. 147, pp. 319–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. R. M. Esper, M. S. Pankonin, and J. A. Loeb, “Neuregulins: versatile growth and differentiation factors in nervous system development and human disease,” Brain Research Reviews, vol. 51, no. 2, pp. 161–175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-G. Hahn, H.-Y. Wang, D.-S. Cho et al., “Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia,” Nature Medicine, vol. 12, no. 7, pp. 824–828, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Z. Chong, M. Thompson, S. Beltaifa, M. J. Webster, A. J. Law, and C. S. Weickert, “Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients,” Schizophrenia Research, vol. 100, no. 1–3, pp. 270–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Rujescu, A. Bender, M. Keck et al., “A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities,” Biological Psychiatry, vol. 59, no. 8, pp. 721–729, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Kondziella, E. Brenner, E. M. Eyjolfsson, K. R. Markinhuhta, M. L. Carlsson, and U. Sonnewald, “Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure,” Neuropsychopharmacology, vol. 31, no. 9, pp. 1880–1887, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. W. Olney and N. B. Farber, “Glutamate receptor dysfunction and schizophrenia,” Archives of General Psychiatry, vol. 52, no. 12, pp. 998–1007, 1995. View at Google Scholar · View at Scopus
  25. J. D. Jentsch and R. H. Roth, “The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia,” Neuropsychopharmacology, vol. 20, no. 3, pp. 201–225, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. G. E. Duncan, S. Miyamoto, J. N. Leipzig, and J. A. Lieberman, “Comparison of brain metabolic activity patterns induced by ketamine, MK- 801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine,” Brain Research, vol. 843, no. 1-2, pp. 171–183, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. D. R. Weinberger, M. S. Aloia, T. E. Goldberg, and K. F. Berman, “The frontal lobes and schizophrenia,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 6, no. 4, pp. 419–427, 1994. View at Google Scholar
  28. B. Elvevag and T. E. Goldberg, “Cognitive impairment in schizophrenia is the core of the disorder,” Critical Reviews in Neurobiology, vol. 14, no. 1, pp. 1–21, 2000. View at Google Scholar · View at Scopus
  29. D. P. Eisenberg and K. F. Berman, “Executive function, neural circuitry, and genetic mechanisms in schizophrenia,” Neuropsychopharmacology, vol. 35, no. 1, pp. 258–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. S. Seo, S. H. Kim, Y. M. Ahn et al., “The effects of repeated administrations of MK-801 on ERK and GSK-3ß signalling pathways in the rat frontal cortex,” International Journal of Neuropsychopharmacology, vol. 10, no. 3, pp. 359–368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinate, Academic Press, San Diego, Calif, USA, 2005.
  32. X.-D. Wang, Y.-A. Su, C.-M. Guo, Y. Yang, and T.-M. Si, “Chronic antipsychotic drug administration alters the expression of neuregulin 1β, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus,” International Journal of Neuropsychopharmacology, vol. 11, no. 4, pp. 553–561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. D. A. Gearhart, M.-L. Middlemore, and A. V. Terry, “ELISA methods to measure cholinergic markers and nerve growth factor receptors in cortex, hippocampus, prefrontal cortex, and basal forebrain from rat brain,” Journal of Neuroscience Methods, vol. 150, no. 2, pp. 159–173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. R. A. G. Garcia, K. Vasudevan, and A. Buonanno, “The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at neuronal synapses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3596–3601, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Z. Huang, S. Won, D. W. Ali et al., “Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses,” Neuron, vol. 26, no. 2, pp. 443–455, 2000. View at Google Scholar · View at Scopus